Additional Toxicities in GPRC5D-Directed Bispecifics for RRMM
Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical treatments, and prophylactic nail care. These toxicities are generally less severe than those of BCMA-targeted bispecifics, which often present with more systemic CRS and neurotoxicity.
Video content above is prompted by the following:
- After the first month of treatment, the patient achieved stringent complete response (sCR) but is experiencing the following symptoms: oral, skin, and nail toxicities.
- What mitigation strategies would you initiate for this patient?
- How do those toxicities compare with those of other bispecifics (ie, BCMA-directed) in this space?
Peers Evaluate CAR T Referral and Bridging Process for Early Relapsed Multiple Myeloma
December 26th 2024During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with lenalidomide-refractory multiple myeloma after 1 prior line of therapy.
Read More
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
